



UNITED STATES
NUCLEAR REGULATORY COMMISSION

REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PA 19406-1415

October 3, 2000

Docket No. 03003131
Control No. 128680

License No. 37-11079-01

Larry A. Crowell
President & CEO
Sewickley Valley Hospital
720 Blackburn Road
Sewickley, PA 15143

SUBJECT: SEWICKLEY VALLEY HOSPITAL, ISSUANCE OF LICENSE AMENDMENT,
CONTROL NO. 128680

Dear Mr. Crowell:

This refers to your license amendment request. Enclosed with this letter is the amended license.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5093 or 5239, so that we can provide appropriate corrections and answers.

Thank you for your cooperation.

Sincerely,

Original signed by Michelle Beardsley

Michelle Beardsley
Health Physicist
Nuclear Materials Safety Branch 1
Division of Nuclear Materials Safety

Enclosure:
Amendment No. 32

DOCUMENT NAME: C:\137-11079-01.128680.10032000.wpd

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI	DNMS/RI		
NAME	MBeardsley/mrb /s/					
DATE	10/03/2000					

OFFICIAL RECORD COPY

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Sewickley Valley Hospital</p> <p>2. 720 Blackburn Road Sewickley, Pennsylvania 15143</p>	<p>In accordance with the letter dated September 13, 2000,</p> <p>3. License number 37-11079-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date May 31, 2002</p> <hr/> <p>5. Docket No. 030-03131 Reference No.</p>
------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material identified in 10 CFR 35.100</p> <p>B. Any byproduct material identified in 10 CFR 35.200</p> <p>C. Any byproduct material identified in 10 CFR 35.300</p> <p>D. Any byproduct material identified in 10 CFR 31.11</p> <p>E. Gadolinium 153</p>	<p>7. Chemical and/or physical form</p> <p>A. Any radiopharmaceutical identified in 10 CFR 35.100</p> <p>B. Any radiopharmaceutical identified in 10 CFR 35.200 except generators and gas</p> <p>C. Any radiopharmaceutical identified in 10 CFR 35.300</p> <p>D. Prepackaged Kit</p> <p>E. Sealed Source (North American Scientific Model MED3601)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 500 millicuries</p> <p>D. As needed</p> <p>E. Not to exceed 250 millicuries per source and 1100 millicuries total</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

<p>9. Authorized use:</p> <p>A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.</p> <p>B. Any imaging and localization procedure approved in 10 CFR 35.200.</p> <p>C. Any radiopharmaceutical therapy procedure approved in 10 CFR 35.300.</p> <p>D. <u>In vitro</u> studies.</p> <p>E. For use in an ADAC Laboratories Model Vantage device for patient attenuation correction during S.P.E.C.T. imaging.</p>

CONDITIONS

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
37-11079-01

Docket or Reference Number
030-03131

Amendment No. 32

10. Licensed material may be used only at the licensee's facilities located at 720 Blackburn Road, Sewickley, Pennsylvania.
11. The Radiation Safety Officer for this license is Robin L. Greenspan, M.D.
12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users

Material and Use

Thomas Havrilla, M. D.

35.100; 35.200; 35.300; In vitro studies
Gadolinium 153 for patient attenuation correction
during S.P.E.C.T. imaging

Jack M. Preston, M. D.

35.100; 35.200; 35.300 except thyroid carcinoma

Thomas Kavic, M. D.

35.100; 35.200; 35.300; In vitro studies

Daniel Greenler, M. D.

35.100; 35.200; In vitro studies

Azizeh H. Djafari, M.D.

In vitro studies

Edward Estrin, M.D.

35.100; 35.200; 35.300

Lisa V. Ross, M.D.

35.100; 35.200

Nadeem Iqbal, M.D.

35.100; 35.200

Robin L. Greenspan, M.D.

35.100; 35.200; 35.300

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d), 40.36(b), and 70.25(d) for establishing financial assurance for decommissioning.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
37-11079-01Docket or Reference Number
030-03131

Amendment No. 32

14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material at a single location to quantities below the limits specified in 10 CFR 30.72 which require consideration of the need for an emergency plan for responding to a release of licensed material.
15. A. Sealed sources and detector cells containing licensed material shall be tested for leakage and/or contamination at intervals not to exceed six months or at such other intervals as are specified by the certificate of registration referred to in 10 CFR 32.210, not to exceed three years.
- B. Notwithstanding Paragraph A of this Condition, sealed sources designed to emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed three months.
- C. In the absence of a certificate from a transferor indicating that a leak test has been made within six months prior to the transfer, a sealed source or detector cell received from another person shall not be put into use until tested.
- D. Each sealed source fabricated by the licensee shall be inspected and tested for construction defects, leakage, and contamination prior to any use or transfer as a sealed source.
- E. Sealed sources and detector cells need not be leak tested if:
- (i) they contain only hydrogen-3; or
 - (ii) they contain only a radioactive gas; or
 - (iii) the half-life of the isotope is 30 days or less; or
 - (iv) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or
 - (v) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transfer to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
37-11079-01Docket or Reference Number
030-03131

Amendment No. 32

- F. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission and the source or detector cell shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within five days of the date the leak test result is known with the appropriate U. S. Nuclear Regulatory Commission, Regional Office referenced in Appendix D of 10 CFR Part 20. The report shall specify the source or detector cell involved, the test results, and corrective action taken.
- G. The licensee is authorized to collect leak test samples for analysis by the licensee. Alternatively, tests for leakage and/or contamination may be performed by persons specifically licensed by the Commission or an Agreement State to perform such services.
16. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
17. The licensee shall not acquire licensed material in a sealed source or device unless the source or device has been registered with the U.S. Nuclear Regulatory Commission pursuant to 10 CFR 32.210 or equivalent regulations of an Agreement State.
18. The licensee shall conduct a physical inventory every three months to account for all sealed sources and devices containing licensed material received and possessed pursuant to 10 CFR 35.57, 35.400 and 35.500 and every six months for all other sealed sources and devices.
19. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
37-11079-01Docket or Reference Number
030-03131

Amendment No. 32

20. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated March 27, 1991
 - B. Letters dated February 28, 1992
 - C. Letter dated March 20, 1992
 - D. Letter dated October 14, 1992
 - E. Letter dated September 17, 1993
 - F. Letter dated June 19, 1995
 - G. Letter dated September 26, 1995
 - H. Letter dated June 16, 1999



For the U.S. Nuclear Regulatory Commission

Original signed by Michelle Beardsley

By _____

Michelle Beardsley
Nuclear Materials Safety Branch 1
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406Date October 3, 2000